emerging glp-1 gip obesity treatments 2025 Market Size to Hit USD 66.57 Billion by 2035 GLP-1 Agonists For Obesity In

Whether or not to cover GLP-1s is no longer the questionits how to cover them most effectively

Summary In summary, GLP-1 RA based therapies are being rigorously studied in management of MASLD in particular more advanced stages and likely will become foundational therapies in the future.

Significance statement ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest

Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.

New podcast episode explores research finding GLP-1 drugs live up to their promise in everyday medical care but, at least in the short run, they do not reduce overall hea